Prospective Assessment of Patient-Reported Outcomes and Estradiol and Drug Concentrations in Patients Experiencing Toxicity from Adjuvant Aromatase Inhibitors

Abstract

Purpose Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in post-menopausal women, are associated with toxicities that limit adherence. Approximately one-third of patients will tolerate a different AI after not tolerating the first. We report the effect of crossover from exemestane to letrozole or vice versa on patient-reported outcomes (PROs) and whether the success of crossover is due to lack of estrogen suppression.

Publication
Breast Cancer Research and Treatment

Related